Humaid Al-Shamsi, Chief Executive Officer at Burjeel Cancer Institute and Regional Director of Burjeel Oncology GCC at Burjeel Holdings, shared on LinkedIn:
“Pleased to share my 33rd peer-reviewed publication of 2026:
‘Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait’
Authors: Humaid O. Al-Shamsi, Mohamed Farghaly, Ammar Abdaljalil, Abdulwahab Al-Tourah, Chana Saad, Youmna Bassil, Ghadah Albassam, Rami Nimer, Monika Naroz, Omar El-Badry, Rony Akel.
Read The Full Article.
Published in Clinical Drug Investigation, this study evaluates the potential clinical and economic impact of PD-1/PD-L1 immunotherapy across the UAE, Oman, and Kuwait, providing important regional evidence to inform treatment, reimbursement and healthcare policy.
Reaching 33 peer-reviewed publications this year is a milestone that I believe places me among the most prolific publishing oncologists in the MENA region, if not the most prolific this year.
More important than the number itself is the purpose behind it: generating meaningful evidence from our region, for our patients, and contributing to the advancement of cancer care globally.
Grateful to all my co-authors and collaborators.”